Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Aug;123(8):673-9.
doi: 10.1248/yakushi.123.673.

[Identification of the ligand binding sites and novel drug target molecules by photoaffinity labeling]

[Article in Japanese]
Affiliations
Free article
Review

[Identification of the ligand binding sites and novel drug target molecules by photoaffinity labeling]

[Article in Japanese]
Akihiko Kuniyasu. Yakugaku Zasshi. 2003 Aug.
Free article

Abstract

Photoaffinity labeling is a useful and reliable method for 1) the identification of the ligand-target receptor and 2) the structural investigation of its binding site. Using photoaffinity labeling techniques, the binding sites of four typical calcium antagonists, 1,4-dihydropyridines, benzothiazepines, phenylalkylamines, and benzothiazines, were successfully identified within the primary structure of the skeletal muscle calcium channels. The results confirm pharmacological observations of the four antagonists, which had been proposed to interact allosterically with each other. Secondarily we demonstrated that human glutathione S-transferase class pi (GST pi) is specifically photolabeled by the antidiabetic agent sulfonylurea glibenclamide (GB) and it also inhibits the enzyme activities of glutathione conjugation by GB in a competitive manner for glutathione. These results indicate that GST pi is another target molecule of sulfonylurea since a subunit of ATP-sensitive potassium channels is well known to be a sulfonylurea receptor. This review focuses on photoaffinity labeling techniques as a useful tool for drug discovery and development.

PubMed Disclaimer

Similar articles